Novo Nordisk regained its position as Europe's most valuable company with a market cap of 367 billion, surpassing SAP. The stock rose 2% in Denmark following positive news about advancing amycretin, a next-generation obesity drug, to phase III trials. The company also signed an 812m research deal with Deep Apple to develop non-GLP-1 drugs, aiming to retain market share in the weight loss space.